Yesterday, Jan. 21, 2016, 50 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $10.00 to $2,727,667.28.

Highlighted Stocks Traded by Insiders:

NxStage Medical (NXTM) - FREE Research Report

Turk Joseph E Jr, who is President at NxStage Medical, sold 2,000 shares at $18.75 on Jan. 21, 2016. Following this transaction, the President owned 108,663 shares meaning that the stake was reduced by 1.81% with the 2,000-share transaction.

The shares most recently traded at $19.93, up $1.18, or 5.92% since the insider transaction. Historical insider transactions for NxStage Medical go as follows:

  • 4-Week # shares bought: 10,150
  • 4-Week # shares sold: 1,500
  • 12-Week # shares bought: 10,150
  • 12-Week # shares sold: 23,853
  • 24-Week # shares bought: 10,150
  • 24-Week # shares sold: 38,993

The average volume for NxStage Medical has been 557,100 shares per day over the past 30 days. NxStage Medical has a market cap of $1.2 billion and is part of the health care sector and health services industry. Shares are down 11.18% year-to-date as of the close of trading on Thursday.

NxStage Medical, Inc., a medical device company, develops, manufactures, and markets products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures. Currently, there are 5 analysts who rate NxStage Medical a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on NXTM - FREE

TheStreet Quant Ratings

rates NxStage Medical as a

hold

. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full

NxStage Medical Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Stemline Therapeutics (STML) - FREE Research Report

Gionco David, who is Chief Accounting Officer at Stemline Therapeutics, sold 3,217 shares at $4.82 on Jan. 21, 2016. Following this transaction, the Chief Accounting Officer owned 35,244 shares meaning that the stake was reduced by 8.36% with the 3,217-share transaction.

The shares most recently traded at $5.16, up $0.34, or 6.63% since the insider transaction. Historical insider transactions for Stemline Therapeutics go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 12,235
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 12,235
  • 24-Week # shares bought: 2,000
  • 24-Week # shares sold: 12,235

The average volume for Stemline Therapeutics has been 129,400 shares per day over the past 30 days. Stemline Therapeutics has a market cap of $86.6 million and is part of the health care sector and drugs industry. Shares are down 19.33% year-to-date as of the close of trading on Thursday.

Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary therapeutics for cancer stem cells and bulk tumors in the United States. Currently, there are 6 analysts who rate Stemline Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on STML - FREE

TheStreet Quant Ratings

rates Stemline Therapeutics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Stemline Therapeutics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ares Capital (ARCC) - FREE Research Report

Bartlett Steve, who is Director at Ares Capital, bought 100 shares at $13.20 on Jan. 21, 2016. Following this transaction, the Director owned 5,100 shares meaning that the stake was boosted by 2% with the 100-share transaction.

The shares most recently traded at $13.74, up $0.54, or 3.93% since the insider transaction. Historical insider transactions for Ares Capital go as follows:

  • 4-Week # shares bought: 100
  • 12-Week # shares bought: 5,310
  • 24-Week # shares bought: 48,606

The average volume for Ares Capital has been 1.8 million shares per day over the past 30 days. Ares Capital has a market cap of $4.3 billion and is part of the financial sector and financial services industry. Shares are down 5.96% year-to-date as of the close of trading on Thursday.

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. The stock currently has a dividend yield of 11.5%. The company has a P/E ratio of 8.0. Currently, there are 10 analysts who rate Ares Capital a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARCC - FREE

TheStreet Quant Ratings

rates Ares Capital as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and good cash flow from operations. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Ares Capital Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.